German bioinformatics startup 4HF Biotec targets early-stage biotech development with technology to predict drug sensitivity based on tumor genetic profiles.
The partners will offer an end-to-end microbiome sequencing and analysis service through Transnetyx's global network of model organism research customers.
Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.
NHGRI has moved the Genotype-Tissue Expression dataset entirely to the cloud in an effort to democratize access to the huge but formerly pricey compendium.
Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.
